Stephen Willey
Stock Analyst at Stifel
(3.09)
# 1,229
Out of 4,670 analysts
120
Total ratings
39.56%
Success rate
2.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stephen Willey
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XFOR X4 Pharmaceuticals | Maintains: Buy | $5 → $4 | $0.34 | +1,083.43% | 2 | Nov 14, 2024 | |
| IGMS IGM Biosciences | Maintains: Buy | $25 → $27 | $8.89 | +203.71% | 6 | Nov 11, 2024 | |
| ABCL AbCellera Biologics | Reiterates: Buy | $14 → $12 | $2.76 | +334.78% | 4 | Nov 5, 2024 | |
| ZYME Zymeworks | Maintains: Buy | $21 → $28 | $14.29 | +95.94% | 6 | Oct 28, 2024 | |
| EXEL Exelixis | Maintains: Hold | $26 → $30 | $35.61 | -15.75% | 16 | Oct 16, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Buy | $47 | $18.09 | +159.81% | 1 | Oct 8, 2024 | |
| CUE Cue Biopharma | Maintains: Buy | $8 → $4 | $1.02 | +292.16% | 7 | Aug 20, 2024 | |
| INSM Insmed | Maintains: Buy | $74 → $88 | $73.15 | +20.30% | 4 | Aug 9, 2024 | |
| HLVX HilleVax | Downgrades: Hold | $34 → $3 | $1.86 | +61.29% | 3 | Jul 9, 2024 | |
| GERN Geron | Maintains: Buy | $6 → $7 | $4.07 | +71.99% | 2 | Jun 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 | $22.05 | +22.45% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $6 → $1.5 | $0.58 | +159.25% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $29 → $7 | $3.24 | +116.05% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $7 | $2.78 | +151.80% | 10 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $12 | $0.79 | +1,418.99% | 4 | Mar 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $68 | $71.72 | -5.19% | 4 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $4 | $1.41 | +183.69% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $62 | $41.15 | +50.67% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $2.45 | +634.69% | 2 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.49 | +504.03% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $3.92 | +206.12% | 1 | Nov 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $228 → $288 | $4.07 | +6,976.17% | 4 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $285 | $0.34 | +84,898.51% | 1 | Mar 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $21 | $1.16 | +1,710.34% | 2 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 → $4 | $0.86 | +363.28% | 7 | Jul 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $123 | $244.89 | -49.77% | 3 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $48 → $47 | $34.01 | +38.19% | 2 | Aug 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $102 → $109 | $64.26 | +69.62% | 3 | Aug 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Terminates: Hold | n/a | $19.15 | - | 2 | Jun 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $0.32 | +7,791.41% | 5 | Mar 7, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $23 | $6.63 | +246.91% | 5 | Feb 7, 2018 |
X4 Pharmaceuticals
Nov 14, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $0.34
Upside: +1,083.43%
IGM Biosciences
Nov 11, 2024
Maintains: Buy
Price Target: $25 → $27
Current: $8.89
Upside: +203.71%
AbCellera Biologics
Nov 5, 2024
Reiterates: Buy
Price Target: $14 → $12
Current: $2.76
Upside: +334.78%
Zymeworks
Oct 28, 2024
Maintains: Buy
Price Target: $21 → $28
Current: $14.29
Upside: +95.94%
Exelixis
Oct 16, 2024
Maintains: Hold
Price Target: $26 → $30
Current: $35.61
Upside: -15.75%
Bicara Therapeutics
Oct 8, 2024
Initiates: Buy
Price Target: $47
Current: $18.09
Upside: +159.81%
Cue Biopharma
Aug 20, 2024
Maintains: Buy
Price Target: $8 → $4
Current: $1.02
Upside: +292.16%
Insmed
Aug 9, 2024
Maintains: Buy
Price Target: $74 → $88
Current: $73.15
Upside: +20.30%
HilleVax
Jul 9, 2024
Downgrades: Hold
Price Target: $34 → $3
Current: $1.86
Upside: +61.29%
Geron
Jun 10, 2024
Maintains: Buy
Price Target: $6 → $7
Current: $4.07
Upside: +71.99%
May 15, 2024
Maintains: Buy
Price Target: $27
Current: $22.05
Upside: +22.45%
May 15, 2024
Downgrades: Hold
Price Target: $6 → $1.5
Current: $0.58
Upside: +159.25%
May 10, 2024
Downgrades: Hold
Price Target: $29 → $7
Current: $3.24
Upside: +116.05%
Apr 12, 2024
Maintains: Hold
Price Target: $7
Current: $2.78
Upside: +151.80%
Mar 21, 2024
Maintains: Buy
Price Target: $15 → $12
Current: $0.79
Upside: +1,418.99%
Mar 12, 2024
Reiterates: Hold
Price Target: $68
Current: $71.72
Upside: -5.19%
Dec 19, 2023
Maintains: Buy
Price Target: $3 → $4
Current: $1.41
Upside: +183.69%
Dec 18, 2023
Maintains: Buy
Price Target: $53 → $62
Current: $41.15
Upside: +50.67%
May 12, 2023
Maintains: Buy
Price Target: $21 → $18
Current: $2.45
Upside: +634.69%
Jan 27, 2023
Initiates: Buy
Price Target: $9
Current: $1.49
Upside: +504.03%
Nov 28, 2022
Initiates: Buy
Price Target: $12
Current: $3.92
Upside: +206.12%
Jun 26, 2020
Downgrades: Hold
Price Target: $228 → $288
Current: $4.07
Upside: +6,976.17%
Mar 25, 2020
Initiates: Buy
Price Target: $285
Current: $0.34
Upside: +84,898.51%
Mar 17, 2020
Maintains: Buy
Price Target: $22 → $21
Current: $1.16
Upside: +1,710.34%
Jul 29, 2019
Downgrades: Hold
Price Target: $10 → $4
Current: $0.86
Upside: +363.28%
Aug 13, 2018
Maintains: Buy
Price Target: $125 → $123
Current: $244.89
Upside: -49.77%
Aug 8, 2018
Maintains: Hold
Price Target: $48 → $47
Current: $34.01
Upside: +38.19%
Aug 3, 2018
Maintains: Buy
Price Target: $102 → $109
Current: $64.26
Upside: +69.62%
Jun 25, 2018
Terminates: Hold
Price Target: n/a
Current: $19.15
Upside: -
Mar 7, 2018
Maintains: Buy
Price Target: $23 → $25
Current: $0.32
Upside: +7,791.41%
Feb 7, 2018
Maintains: Buy
Price Target: $20 → $23
Current: $6.63
Upside: +246.91%